PFIZER INC 8-K

What Happened
Pfizer Inc. announced its financial results for the first quarter of 2026 and furnished a press release reporting those results in an 8‑K filed May 5, 2026. The 8‑K was filed under Item 2.02 (Results of Operations and Financial Condition) and the press release is included as Exhibit 99.

Key Details

• Filing date: May 5, 2026; Item 2.02 covers quarterly results for Q1 2026.
• Exhibit 99: press release reporting Pfizer’s Q1 2026 financial results (furnished with the 8‑K).
• Exhibit 104: cover page Inline XBRL tags embedded for interactive data.
• Report signed by Margaret M. Madden, Senior Vice President and Corporate Secretary, dated May 5, 2026.

Why It Matters
This 8‑K notifies investors that Pfizer has publicly reported its Q1 2026 earnings and made the press release available as an SEC exhibit. The filing itself does not include line‑item financial statements beyond the press release, so investors should review Exhibit 99 (the press release) or Pfizer’s investor relations materials for revenue, earnings per share, segment performance, and any updated guidance or management commentary disclosed with the results.